期刊文献+

PARP-1在乳腺癌组织中的表达和临床意义 被引量:3

原文传递
导出
摘要 目的探讨聚ADP核糖聚合酶-1(PARP-1)在乳腺癌组织中的表达及其与临床特征的关系。方法采用免疫组化方法检测58例乳腺癌和11例乳腺良性疾病石蜡包埋标本中PARP-1的表达情况,分析乳腺癌与乳腺良性疾病组织中两者表达差异及乳腺癌组织中PARP-1的阳性表达与临床参数(患者年龄、术后病理分期、肿瘤体积的大小、淋巴结转移状况等指标)的相关性。结果乳腺癌组织中PARP-1的阳性表达率(63.79%)显著高于乳腺良性疾病的阳性表达率(9.09%),P=0.01,乳腺癌标本中有淋巴结转移者的PARP-1阳性表达率(80.00%)高于无淋巴结转移者(51.52%),P=0.031。结论 PARP-1在乳腺癌组织中的表达与淋巴结转移状况有关。PARP-1表达上调可能与乳腺癌的恶性生物学特性有关,从而对乳腺癌的临床诊疗及预后的判断具有一定临床价值。
出处 《中国妇幼保健》 CAS 2015年第24期4220-4222,共3页 Maternal and Child Health Care of China
  • 相关文献

参考文献18

  • 1陈万青,张思维,曾红梅,郑荣寿,邹小农,赵平,吴良有,李光琳,赫捷.中国2010年恶性肿瘤发病与死亡[J].中国肿瘤,2014,23(1):1-10. 被引量:882
  • 2Virág L,SzabóC.The therapeutic potential of poly(ADP-ribose)polymerase inhibitors〔J〕.Pharmacol Revi,2002,54(3):375-429. 被引量:1
  • 3Brown RS,Wahl RL.Overexpression of Glut‐1 glucose transporter in human breast cancer.An immunohistochemical study〔J〕.Cancer,1993,72(10):2979-2985. 被引量:1
  • 4AméJC,Spenlehauer C,de Murcia G.The PARP superfamily〔J〕.Bioessays,2004,26(8):882-893. 被引量:1
  • 5Otto H,Reche PA,Bazan F,et al.In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases(p ARTs)〔J〕.BMC Genomics,2005,6(1):139. 被引量:1
  • 6Cho BB,Toledo-Pereyra LH.Caspase-independent programmed cell death following ischemic stroke〔J〕.Invest Surg,2008,21(3):141-147. 被引量:1
  • 7Moroni F.Poly(ADP-ribose)polymerase-l(PARP-1)and postischemic brain damage〔J〕.Curr Opin Pharmacol,2008,8(1):96-103. 被引量:1
  • 8Wang X,Liu L,Montagna C,et al.Haploinsufficiency of Parp-1 accelerates Brca-l-associated centrosome amplification,telomere shortening,genetic instability,apoptosis,and embryonic lethality〔J〕.Cell Death Differ,2007,14(5):924-931. 被引量:1
  • 9Ossovskaya V,Koo IC,Kaldjian EP,et al.Upregulation of poly(ADP-ribose)polymerase-1(PARP1)in triple-negative breast cancer and other primary human tumor types〔J〕.Genes cancer,2010,1(8):812-821. 被引量:1
  • 10邵志敏,沈镇宙.乳腺癌的预后因素研究进展[J].中国癌症杂志,2001,11(5):396-400. 被引量:22

二级参考文献13

  • 1[1]Saimura M, Fukutomi T, Tsuda H,et al. Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor[J]. J Surg Oncol,1999,71(2):101-105. 被引量:1
  • 2[2]Fleming ST, Rastogi A, Dmitrienko A,et al. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer[J]. Med Care,1999,37(6):601-614. 被引量:1
  • 3[3]Masood S. Prognostic factors in breast cancer[J]. Breast J,1997,5(2):267-283. 被引量:1
  • 4[4]Tagliabue E, Menard S, Robertson JF,et al. c-erbB-2 expression in primary breast cancer[J]. Int J Biol Markers,1999,14(1):16-26. 被引量:1
  • 5[5]Dowlatshahi K, Fan M, Snider HC, et al. Lymph node micrometastases from bresat carcinoma: reviewing the dilemma[J]. Cancer,1997,80(7):1188-1197. 被引量:1
  • 6[6]Diab SG, Clark GM, Osborne CK et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol,1999,17(5):1442-1448. 被引量:1
  • 7[7]Carriago MT, Henson DE. The histological grading of cancer[J]. Cancer,1995,75(4):406-421. 被引量:1
  • 8[8]Sauerbrei W, Hubner K, Schmoer C. Validation of existing and development of new prognostic classification schemes in node negative breast cancer[J]. Breast Cancer Res Treat,1997,42(2):146-163. 被引量:1
  • 9[9]Ravdin PM. A computer program to assist in making breast cancer adjuvant therapy decision[J]. Semin Oncol,1996,23(Suppl 2):43-50. 被引量:1
  • 10[10]Gonzalez-Vela MC, Garijo MF, Fernandez F, et al. Cathepsin D in host stromal cells is associated with more highly vascular and aggressive invasive breast carcinoma[J]. Histopathology,1999,34(1):35-42 被引量:1

共引文献902

同被引文献17

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部